Sep 09, 2019
Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy
Sep 03, 2019
Phio Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Healthcare Conference
Aug 15, 2019
Phio Pharmaceuticals and Helmholtz Zentrum München to Collaborate on Novel Targets for the Use of Self-Delivering RNAi In T Cell and NK Cell Adoptive Cell Therapy Therapeutics
Aug 13, 2019
RNAi Technologies Market 2019, Industry Analysis, Competitors Strategy, Trends and Demands, Key Applications, Forecast To 2025
Aug 12, 2019
Global RNAi Research Report 2019: Technologies are Described, Along with Design and Methods of Manufacture of siRNA Reagents
Aug 07, 2019
Evox Therapeutics Granted Key Exosome Patents Covering RNA Therapeutics and Targeted Drug Delivery
Jul 23, 2019
Alnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada
Jul 18, 2019
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Jun 05, 2019
RNA Therapies in Oncology Analytical Tool: 127 Companies, 274 RNA Therapy Drugs, 182 in Active Development in Cancer Across 122 Different Targets
Apr 26, 2019
Sirnaomics Closes $47 Million Series C Financing to Develop RNAi Therapeutics for Treatment of Cancer and Fibrotic Diseases
Apr 08, 2019
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Mar 25, 2019
Phio Pharmaceuticals to Present Poster on the Use of Self-Delivering RNAi in Immuno-oncology at the AACR Annual Meeting 2019
Jan 09, 2019
/CORRECTION/ -- NapaJen Pharma, Inc./
Jan 09, 2019
NapaJen Pharma Closes $12.4 Million Series C Financing
Dec 04, 2018
Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13
Nov 07, 2018
RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018
Oct 19, 2018
Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial
Oct 04, 2018
Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
Oct 03, 2018
RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering
Sep 26, 2018
RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference